Back to YC Companies
Eugit Therapeutics
Summer 2022
Active
Enabling Tissue Targeting of Therapies
2 people View on YC
Eugit Therapeutics at a glance
- Y Combinator batch
- Summer 2022
- Status
- Active
- Industry
- Healthcare
- Team size
- 2 people
- Location
- Not recorded
- Website
- Not recorded
Every field above comes from the Y Combinator company record. Nothing is estimated.
About Eugit Therapeutics
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Tags:
Cell Therapy
Synthetic Biology
Therapeutics
Oncology
Biotechnology